Extended data Fig. 4: Sequence analysis of study-emergent CA mutations.
From: Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
a, Longitudinal CA sequence analysis of select plasma samples from viremic study animals. Samples with population-scale wild-type and V11A CA sequences are shaded grey and blue, respectively, whereas yellow boxes denote sequence failures. b, Alignment of HIV-1 (NL4.3 strain) and SHIV-SF162P3 CA amino-acid sequences. Shaded regions represent invariant residues, hashed lines denote sequence gaps, and red arrows highlight HIV-1 residues associated with GS-CA1 resistance (L56, N57, M66, Q67, K70, N74, T107). c, A single CA monomer (rendered as ribbons in cyan) within the HIV-1 CA hexamer-LEN crystal structure16, with notation of the CA N-terminal and C-terminal domains (CANTD and CACTD, respectively) and a GS-CA1 molecule (carbon atoms shown as green) docked at the LEN binding site. Location of the only CA variant (V11A) transiently detected by bulk sequencing is shown relative to all HIV-1 CA residues associated with bona fide in vitro GS-CA1 and LEN resistance (highlighted as sticks).
